Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals, LLC
Deciphera Pharmaceuticals, LLC
M.D. Anderson Cancer Center
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
Centre Leon Berard
SCRI Development Innovations, LLC
MedImmune LLC